INKT minktherapeutics.com: Enterprise Value to EBITDA Ratio

Graphic logo of MiNK Therapeutics (INKT)

MiNK Therapeutics, Inc. (INKT) focuses on developing oncology immunotherapies, where the leadership's strong scientific foundation and testing transparency are coupled with a dependency on Agenus, which simultaneously serves as a pillar for the development of iNKT-cell therapy. The current exchange quotes based on the EV/EBITDA metric illustrated below are 0.00. US patent security and the humanitarian status of the developments minimize geopolitical risks.

MiNK - INKT Total Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/17/2026)

Summary analytical data breakdowns for MiNK (INKT)

Fundamental company analysis:INKT (MiNK Therapeutics)
Original product of MiNK Therapeutics Inc.

This metric reflects the business value relative to earnings before interest, taxes, depreciation, and amortization, allowing for the identification of asset overvaluation through an analysis of operational efficiency. For MiNK Therapeutics, Inc. (INKT), which is burning capital on clinical trials without commercial products, this valuation serves as an indicator of market expectations, as clearly evidenced by the change in the EV/EBITDA ratio over time.

Competitor analysis for MiNK Therapeutics, Inc.

ImmunityBio Inc - Enterprise Value to EBITDA Ratio|Immunocore (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (Arcus Biosciences)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iovance.com|Enterprise Value to EBITDA Ratio immatics.com (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor Inc (XNCR)|Enterprise Value to EBITDA Ratio Compass Bio CMPX|Replimune Group Inc - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell Pharma LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA IO Biotech Corp (IOBT)|Enterprise Value to EBITDA Ratio STRO|HOWL - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio IMMX (Immix Biopharma, Inc.)|Enterprise Value to Operating Income Before Depreciation Ratio ALXO|EV/EBITDA Multiple CUE (Cue Biopharma Inc.)|Business Value to Operating Income Before Depreciation PDSB|Sonnet BioTherapeutics Holdings Inc. - EV/EBITDA Multiple|Company Value to EBITDA MAIA Bio|Liminatus Pharma (LIMN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics NV - Business Value to Operating Income Before Depreciation|NXTC (nextcure.com) - EV/EBITDA Multiple|EV/EBITDA Multiple leaptx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization intensitytherapeutics.com (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Theriva Biologics Inc - Enterprise Value to EBITDA Ratio|Gritstone Bio (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI (NexImmune) - Enterprise Value to Operating Income Before Depreciation|TSBX (Turnstone Biologics Corp.) - Enterprise Value to EBITDA Ratio|Vaccinex, Inc (VCNX) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Therapeutics